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Articles
Prevalence and attributable health burden of chronic 
respiratory diseases, 1990–2017: a systematic analysis for 
the Global Burden of Disease Study 2017
GBD Chronic Respiratory Disease Collaborators*
Summary
Background Previous attempts to characterise the burden of chronic respiratory diseases have focused only on specific 
disease conditions, such as chronic obstructive pulmonary disease (COPD) or asthma. In this study, we aimed to 
characterise the burden of chronic respiratory diseases globally, providing a comprehensive and up-to-date analysis 
on geographical and time trends from 1990 to 2017.
Methods Using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, we estimated 
the prevalence, morbidity, and mortality attributable to chronic respiratory diseases through an analysis of deaths, 
disability-adjusted life-years (DALYs), and years of life lost (YLL) by GBD super-region, from 1990 to 2017, stratified by 
age and sex. Specific diseases analysed included asthma, COPD, interstitial lung disease and pulmonary sarcoidosis, 
pneumoconiosis, and other chronic respiratory diseases. We also assessed the contribution of risk factors (smoking, 
second-hand smoke, ambient particulate matter and ozone pollution, household air pollution from solid fuels, and 
occupational risks) to chronic respiratory disease-attributable DALYs.
Findings In 2017, 544·9 million people (95% uncertainty interval [UI] 506·9–584·8) worldwide had a chronic 
respiratory disease, representing an increase of 39·8% compared with 1990. Chronic respiratory disease prevalence 
showed wide variability across GBD super-regions, with the highest prevalence among both males and females in 
high-income regions, and the lowest prevalence in sub-Saharan Africa and south Asia. The age-sex-specific 
prevalence of each chronic respiratory disease in 2017 was also highly variable geographically. Chronic respiratory 
diseases were the third leading cause of death in 2017 (7·0% [95% UI 6·8–7·2] of all deaths), behind cardiovascular 
diseases and neoplasms. Deaths due to chronic respiratory diseases numbered 3 914 196 (95% UI 3 790 578–4 044 819) 
in 2017, an increase of 18·0% since 1990, while total DALYs increased by 13·3%. However, when accounting for 
ageing and population growth, declines were observed in age-standardised prevalence (14·3% decrease), age-
standardised death rates (42·6%), and age-standardised DALY rates (38·2%). In males and females, most chronic 
respiratory disease-attributable deaths and DALYs were due to COPD. In regional analyses, mortality rates from 
chronic respiratory diseases were greatest in south Asia and lowest in sub-Saharan Africa, also across both sexes. 
Notably, although absolute prevalence was lower in south Asia than in most other super-regions, YLLs due to 
chronic respiratory diseases across the subcontinent were the highest in the world. Death rates due to interstitial 
lung disease and pulmonary sarcoidosis were greater than those due to pneumoconiosis in all super-regions. 
Smoking was the leading risk factor for chronic respiratory disease-related disability across all regions for men. 
Among women, household air pollution from solid fuels was the predominant risk factor for chronic respiratory 
diseases in south Asia and sub-Saharan Africa, while ambient particulate matter represented the leading risk factor 
in southeast Asia, east Asia, and Oceania, and in the Middle East and north Africa super-region.
Interpretation Our study shows that chronic respiratory diseases remain a leading cause of death and disability 
worldwide, with growth in absolute numbers but sharp declines in several age-standardised estimators since 1990. 
Premature mortality from chronic respiratory diseases seems to be highest in regions with less-resourced health 
systems on a per-capita basis.
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Introduction
Chronic respiratory diseases are diseases of the airways 
and other structures of the lung,1 and are among the 
leading causes of morbidity and mortality worldwide.2 
Some of the most common chronic respiratory diseases 
are asthma, chronic obstructive pulmonary disease 
(COPD), and occupational lung diseases. These disease 
entities are important contributors to the rising burden 
of non-communicable diseases (NCDs) globally.2
The WHO Global Alliance against Chronic Respiratory 
Diseases was established with the goal of reducing the 
burden of chronic respiratory diseases, towards a world 
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in which all people breathe freely, and focuses on the 
needs of people with chronic respiratory diseases in low-
income and middle-income countries.3 Risk factors for 
chronic respiratory diseases are common: at least 2 billion 
people are exposed to the toxic effects of biomass fuel use, 
1 billion are exposed to outdoor air pollution, and 1 billion 
are smokers who expose a near-equal magnitude of 
people to the ill-effects of second-hand smoke.4 Each year, 
it is estimated that 4 million people die prematurely from 
chronic respiratory diseases.5 Although occupational 
respiratory conditions are a well characterised risk factor, 
their magnitude is ill-defined; on the basis of the few 
analyses that exist, around 2 million work-related deaths 
annually are estimated to occur because of work-related 
exposures relevant to respiratory conditions.6
Lung diseases in children under 5 years of age, 
counting both acute infectious processes and chronic 
conditions, are among the most common causes of 
death.7 Notably, asthma is the most common chronic 
condition, affecting about 14% of children globally with 
rising prevalence.8
The Forum of International Respiratory Societies 
considers pneumonia, asthma, COPD, lung cancer, and 
tuberculosis the five most important lung diseases 
worldwide from a prevalence standpoint.5 Although 
chronic respiratory diseases are not curable, various 
forms of treatment can help to control symptoms, 
increase patients’ quality of life, and prevent adverse 
outcomes (including exacerbations) that are associated 
with substantial morbidity, increased health-care use, 
disability, and risk of death.3 Infants and young children 
are particularly susceptible to this continuum of poor 
clinical outcomes.1
Health-care costs for respiratory diseases are an 
increasing burden on the economies of all nations. In 
2019, among 28 EU member states, costs of about 
€380 billion annually were attributable to the care of 
patients with chronic respiratory diseases alone. Included 
in this estimate are the costs of direct primary and 
inpatient health care (the latter estimated to be at least 
€55 billion), the costs of lost productivity (at least 
€42 billion), and the monetised value of disability-
adjusted life-years (DALYs) lost (at least €280 billion).9
Despite these extensive health and economic 
consequences, comprehensive published data on the 
prevalence and distribution of chronic respiratory 
diseases at a global scale are lacking.10–13 The primary 
objective of our analysis was to address this evidence gap, 
by estimating the prevalence and disease burden in terms 
of deaths, DALYs, and DALY components—years lived 
with disability (YLDs) and years of life lost (YLLs)—for 
chronic respiratory diseases as part of the Global Burden 
of Diseases, Injuries, and Risk Factors Study (GBD) 2017. 
We also report on the burden of chronic respiratory 
diseases attributable to a series of causal risk factors 
and characterise the variability in our findings across 
the seven GBD super-regions. Our overarching aim is to 
inform policy makers on the persistent and, in some 
cases, rising burden of chronic respiratory diseases, 
especially given the significance of these findings to 
Research in context
Evidence before this study
Although attempts were made to assess the burden of chronic 
obstructive pulmonary disease (COPD) and asthma in the Global 
Burden of Disease Study (GBD) 2015, there have been no reports 
summarising the burden of all chronic respiratory diseases or a 
comprehensive compilation of prevalence, deaths, and 
disability-adjusted life-years (DALYs) for all chronic respiratory 
diseases worldwide over an extended period. Such monitoring is 
needed to comply with the pre-stated aims of the Sustainable 
Development Goals, which specifically call for a one-third 
reduction in premature mortality from non-communicable 
diseases (NCDs) such as chronic respiratory diseases.
Added value of this study
As part of GBD 2017, we show that prevalence and mortality of 
chronic respiratory diseases are still rising in absolute numbers 
as a result of diverse risk factors, particularly in affluent 
countries. Our finding that nearly 545 million individuals 
currently live with a chronic respiratory condition, representing 
7·4% of the world’s population, provides additional evidence on 
the large health contribution of chronic respiratory diseases to 
premature morbidity and mortality. However, both 
age-standardised mortality and DALY rates per 100 000 people 
show sharp declines between 1990 and 2017. In males and 
females, disability remains highest in south Asia, where 
premature mortality from chronic respiratory diseases is 
highest. Risk factor estimates confirm that smoking remains the 
predominant risk factor for death and disability due to chronic 
respiratory diseases across all regions globally for men. Among 
women, exceptions exist, as household air pollution from solid 
fuels and ambient particulate matter were the leading risk 
factors in areas of Asia and Africa.
Implications of all the available evidence
COPD, asthma, and other chronic respiratory diseases—
including interstitial lung disease, sarcoidosis, and 
pneumoconiosis—are important contributors to the global 
burden of NCDs. Although much of this burden is either 
preventable or treatable with affordable interventions, these 
diseases have received less attention than other NCDs. 
Identifying these up-to-date epidemiological trends in each 
individual chronic respiratory disease is key to informing policy 
decisions on resource allocation and ensuring adequate training 
of national health-care workforces. Our study shows that 
chronic respiratory diseases remain a leading cause of death 
and disability worldwide.
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achieving the health-related Sustainable Development 
Goals (SDGs) by 2030.
Methods
Overview
Methods employed in the GBD 2017 have been extensively 
reported elsewhere.14–17 Attributable deaths, prevalence, 
and DALYs were estimated for up to 359 diseases and 
injuries, as well as 84 behavioural, environmental and 
occupational, and metabolic risks or clusters of risks, for 
195 countries and territories, by 23 age groups and by 
sex, from 1990 to 2017.18 The generic GBD protocol and 
the visualisation tool are accessible online.
As per the GBD Data Dictionary, chronic respiratory 
diseases include the following five categories: asthma, 
COPD, interstitial lung disease and pulmonary sarcoidosis, 
pneumoconiosis (including silicosis, asbest osis, coal-
worker pneumoconiosis, and other pneumo coniosis), and 
other chronic respiratory diseases. The other chronic 
respiratory diseases category comprised obstructive sleep 
apnoea; vasomotor and allergic rhinitis; chronic rhinitis; 
nasopharyngitis and pharyngitis; chronic sinusitis; nasal 
polyposis; other and unspecified disorders of the nose and 
nasal sinuses; chronic diseases of the tonsils and adenoids; 
chronic laryngitis and laryngotracheitis; diseases of the 
vocal cords and larynx, not elsewhere classified; other 
diseases of the upper respiratory tract; airway disease due 
to specific organic dust; hypersensitivity pneumonitis due 
to organic dust; respiratory conditions due to inhalation 
of chemicals, gases, fumes, and vapours; respiratory 
conditions due to other external agents; respiratory 
conditions due to other specified external agents; pul-
monary eosinophilia, not elsewhere classified; pleural 
effusion in conditions classified elsewhere; pleural plaque 
with presence of asbestos; and pleural plaque without 
asbestos. Note that infectious diseases such as tuberculosis 
were not included, even though it is one of the most 
prevalent respiratory conditions.5
The source data, including case definitions, epidemio-
logical estimators, exposures, risk estimates, are freely 
available at the Global Health Data Exchange (GHDx). 
Method write-ups for each cause and risk factor are 
available in appendix 1 (pp 5, 33).
This study is compliant with the Guidelines for 
Accurate and Transparent Health Estimates Reporting.19
Prevalence
The prevalence of chronic respiratory diseases was 
estimated by location, age, sex, and year using DisMod-
MR version 2.1, a Bayesian regression analytical tool used 
in the GBD study which synthesises variable data sources 
to produce internally consistent estimates of incidence, 
prevalence, remission, and excess mortality.20 The major 
data inputs for estimating the prevalence of chronic 
respiratory diseases were population represent ative 
surveys, smaller prevalence studies in the literature 
identified by a systematic review, and hospital claims data.
The estimation included ascertainment of the severity 
distribution of sequelae, incorporation of disability 
weights, and comorbidity adjustment of sequelae. 
Disability weights (appendix 1 p 61), which quantify the 
relative severity of the sequela on a scale of 0–1, were 
derived from nine population surveys and an open-access 
internet survey using pairwise comparison methods.21 
Notably, prevalence data for interstitial lung disease, 
pulmonary sarcoidosis, and pneumoconiosis were 
derived primarily from hospital inpatient and insurance 
claims data.
YLDs were calculated by multiplying the prevalence of 
each sequela by its disability weight for the corresponding 
health state plus a comorbidity adjustment. The estimation 
of YLDs consists of three main steps: establishing the 
prevalence and incidence of causes and sequelae (health 
states caused by a disease, such as blindness caused by 
diabetes) related to disability, assigning levels of severity 
to those disabilities, and combining prevalence and 
incidence with severity, adjusted for co morbidity, into one 
comprehensive measure of non-fatal health loss. We used 
an updated and extensive body of literature studies, survey 
data, surveillance data, inpatient admission records, 
outpatient visit records, and health insurance claims, and 
additionally used results from cause of death models to 
inform estimates. We then used those data, along with 
tools such as DisMod-MR 2.1, to generate estimates of the 
prevalence and incidence of disability-causing sequelae, 
ensuring consistency between rates of incidence, 
prevalence, remission, and cause of death for each 
condition.
Mortality
All-cause mortality rates were derived from vital 
registration systems, censuses, and surveys, and were 
analysed with demographic methods to correct for 
incompleteness. Causes of death from an extensive 
database of vital registration and verbal autopsy data were 
analysed with GBD’s Cause of Death Ensemble model 
tool to calculate a large number of mixed effects or 
spatiotemporal Gaussian process regression models of 
rates or cause fractions with varying combinations of 
predictive covariates. Predictive validity testing determined 
the optimal ensemble of models. Covariates included 
smoking prevalence, cigarettes per capita, the proportion 
exposed to household air pollution, mean fine particulate 
matter (with a diameter <2·5 µm [PM2·5]) from outdoor air 
pollution, a scalar of the combined exposure to risks for 
individual chronic respiratory diseases, and Socio-
demographic Index. As the sensitivity of verbal autopsy 
algorithms to detect specific chronic respiratory diseases 
is poor, we excluded verbal autopsy from all but the total 
chronic respiratory disease model. Estimates for individual 
chronic respiratory diseases were constrained to the 
estimates for total chronic respiratory disease, and all 
individual causes were constrained to the all-cause 
mortality rates derived from demographic estimation.
For the GBD protocol see 
http://www.healthdata.org/gbd/
about/protocol
For the GBD data visualisation 
tool see https://vizhub.
healthdata.org/gbd-compare/
For the Global Health Data 
Exchange see 
http://ghdx.healthdata.org
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YLLs were obtained by multiplying counts of deaths for 
a cause by the remaining life expectancy in GBD’s 
standard life table on the basis of lowest observed 
mortality rates at each age in any population over 
5 million people. DALYs are the sum of YLLs and YLDs. 
We present both crude estimates, and age-standardised 
rates in appendix 1 (p 62), as relevant. Age-standardised 
rates were based on the GBD global reference population 
(available at GHDx).
Risk estimation
Estimates were composed of six risk factors for COPD 
(smoking, second-hand smoke, household air pollution, 
ambient particulate matter, ozone, and occupational 
particulates, which include coal dust), two risk factors 
for asthma (smoking and occupational exposures), and 
three risk factors for pneumoconiosis (occupational 
particulates, occupational silica, and occupational 
asbestos). Sufficient evidence of causality, availability of 
exposure data, potential for behavioural and other 
modifications, and health policy interest are criteria for 
choosing risks and associated outcomes in GBD. 
Population-attributable fractions of disease outcomes 
were estimated from exposure data, relative risks of 
outcomes, and a theoretical minimum exposure level. 
Population surveys were the main source of exposure 
data on smoking, second-hand smoke, and household 
air pollution. Exposure to ambient particulate matter 
(defined as the population-weighted annual average 
mass concentration of PM2·5 in 1 m³ of air) was estimated 
from satellite data on aerosols in the atmosphere and 
calibrated to observations from ground monitors. 
Exposure to ozone was based on a chemical transport 
model of satellite data.22 Occupational exposures were 
based on the proportion of the working population 
exposed to asthmagens and particulates based on 
distribution of the population in nine occupational 
groups as reported by the International Labour 
Organization.23 Relative risks were derived from pooled 
estimates in meta-analyses of cohort studies. The 
theoretical minimum exposure level was set as zero for 
smoking, second-hand smoke, and the occupational 
exposures. For household air pollution, the minimum 
was defined as no household reporting use of solid fuel 
for cooking. For ambient particulate matter, the 
minimum was set as a uniform distribution between 
the lowest and fifth percentile exposure level from all 
data sources. For ozone, the minimum was set as a 
uniform distribution between the lowest and fifth 
percentile exposure measured in the American Cancer 
Society Cancer Prevention Study-II.24 Unlike disease 
estimates, which are mutually exclusive and collectively 
exhaustive in GBD, risk estimates are based on a 
counterfactual analysis and are therefore not additive. 
Estimates of combinations of risks take mediation into 
account based on the difference in relative risks from 
cohort and trial data that did and did not control for 
another risk as a confounder. After adjustment for 
mediation, risks were combined using a multiplicative 
function to avoid the sum of risks exceeding the total 
Figure 1: All-age chronic respiratory disease prevalence by country in 1990 and 2017
3000–5000 7000–9000 900–11 000 11 000–13 000 13 000–15 000 15 000–17 0005000–7000
Prevalent cases per 100 000 people (all ages)
Females, 1990
Males, 1990
Females, 2017
Males, 2017
See Online for appendix 2
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amount of disease.25 Additional details on the estimation 
process for COPD and asthma risks can be found 
elsewhere.10
Statistical analysis
Uncertainty was estimated by recalculating every outcome 
of interest 1000 times, drawing from distributions of the 
sampling error around input data, corrections for 
measurement error, and estimates of residual non-
sampling error and, in the case of cause of death estimates, 
model selection. Uncertainty intervals (UIs) were defined 
as the 2·5th and 97·5th values of the posterior distributions. 
Differences between estimates were computed at the 
1000-draw level and reported as significant if more than 
95% of values for the difference are either positive or 
negative. All code is freely available at GHDx.
Results
In 2017, an estimated 544· 9 million (95% UI 
506·9–584·9) individuals worldwide had a chronic 
respiratory disease, equivalent to a 39·8% increase 
compared with the number of individuals affected in 
1990 (389·7 million [362·9–416·3]; figure 1). The global 
prevalence in 2017 was around 7·1% (95% UI 6·6–7·7). 
Chronic respiratory diseases were most prevalent across 
the GBD high-income super-region, at 10·6% (9·9–11·3), 
up from 9·7% (9·1–10·3) in 1990 (table 1). By contrast, 
the lowest prevalence was observed in sub-Saharan 
Africa (5·1% [4·5–5·8]) and south Asia (5·5% [5·1–6·0]). 
Latin America and the Caribbean had the largest decline 
(–0·80 percentage points) in chronic respiratory disease 
prevalence over the study period, from 8·1% in 1990 to 
7·3% in 2017. Sub-Saharan Africa and the central Europe, 
eastern Europe, and central Asia super-region also saw 
declines in the prevalence of chronic respiratory diseases 
(table 1).
COPD remained the most prevalent disease-specific 
chronic respiratory disease worldwide in 2017, accounting 
for 55·1% of chronic respiratory disease prevalence 
among men and 54·8% among women globally. The 
relative increase in overall prevalence was 5·9% (1·1–9·8) 
between 1990 and 2017. COPD was most prevalent in the 
central Europe, eastern Europe, and central Asia super-
region, at 6·1% in 2017. The high-income super-region 
had a similar prevalence of 5·9%, representing an 
increase of 1·5 percentage points from the prevalence in 
1990 (4·4%), which was the greatest relative difference 
over the study period. Asthma remained the second 
most prevalent chronic respiratory disease worldwide, 
although, in aggregate, its prevalence had decreased 
since 1990, from 3·9% (3·5–4·4) to 3·6% (3·2–4·0; 
table 1).
By sex, chronic respiratory disease prevalence was 
highest for both males and females in the high-income 
region (figure 1). At the country level, the UK had the 
highest rates in both 1990 and 2017 (country estimates, 
overall and by sex, are provided in appendix 2).
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The age-sex-specific prevalence of each chronic 
respiratory disease in 2017 was highly variable (figure 2). 
Asthma prevalence peaked at 5–9 years of age among 
boys and girls, and was greater among boys than among 
girls up to 9 years of age. However, from age 10 years 
onwards, asthma prevalence was consistently higher 
among females than males. From the onset of adulthood 
to old age, COPD increased monotonically, while the 
contributions of interstitial lung disease, pulmonary 
sarcoidosis, and other chronic respiratory diseases 
decreased relative to all chronic respiratory diseases 
(figure 2). Interstitial lung disease and pulmonary 
sarcoidosis were more prevalent among males than 
among females (appendix 2).
The age-standardised prevalence of chronic respiratory 
diseases was 8157·75 (7663·98–8662·19) cases per 
100 000 in 1990 and 6991·55 (6496·73–7516·36) cases per 
100 000 in 2017, representing a decrease of 14·3% 
(appendix 1 p 62).
There were 3 914 196 (3 790 578–4 044 819) deaths due to 
chronic respiratory diseases in 2017 globally, an increase 
of 18·0% since 1990 (3 317 205 [3 011 594–3 425 405] deaths). 
In total, chronic respiratory diseases accounted for 
51·23 (49·61–52·94) deaths per 100 000 individuals in 
2017, 56·45 (54·32–58·08) per 100 000 males and 
45·97 (42·73–49·34) per 100 000 females (table 2). These 
deaths, in aggregate, accounted for 7·0% (6·8–7·2) of 
total all-cause deaths globally, ranking chronic respir-
atory diseases as the third leading cause of death in 2017, 
just behind cardiovascular diseases (31·8% [31·4–32·2] 
of all deaths) and neoplasms (17·1% [16·8–17·3]). 
However, age-standardised mortality rates of chronic 
respiratory diseases decreased by 42·6% between 1990 
(89·5 [81·2–92·5] deaths per 100 000) and 2017 
(51·4 [49·75–53·1] deaths per 100 000).
COPD was the most common cause of chronic 
respiratory disease-attributable deaths, at 41·9 deaths per 
100 000 individuals (5·7% of total all-cause deaths; 
figure 3, table 2). 46·7 (43·6–49·3) deaths per 100 000 
among men and 37·0 (33·6–39·9) per 100 000 among 
women were attributable to COPD. Worldwide, asthma 
was the second leading cause of death among chronic 
respiratory diseases.
Geographically, deaths attributable to chronic respiratory 
disease were most frequent in the south Asia super-region 
(81·2 deaths [75·4–86·3] per 100 000 individuals) in 2017, 
and least frequent in sub-Saharan Africa (15·5 deaths 
[14·4–17·0] per 100 000 Individuals; figure 3). COPD was 
the most common cause of deaths attributable to chronic 
respiratory disease in each individual super-region. The 
second most common cause of chronic respiratory deaths 
was asthma, in all but three super-regions. The exceptions 
were interstitial lung disease and pulmonary sarcoidosis in 
the high-income region (5·9 deaths [4·0–6·6] per 100 000), 
Latin America and the Caribbean region (0·3 deaths 
[0·2–0·4] per 100 000), and central Europe, eastern Europe, 
and central Asia super-regions (1·2 deaths [1·0–1·7] 
per 100 000; figure 3).
Figure 2: Global age-sex-specific prevalence of chronic respiratory diseases by disease category in 2017
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Overall, there were 112 316 763 DALYs (95% UI 
104 649 690–119 692 783) due to chronic respiratory 
diseases in 2017 globally, an increase of 13·3% since 1990 
(99 103 908 DALYs [91 717 116–104 764 799]). In south Asia, 
the majority of DALYs were the result of the high YLL rate 
in this region (1567·1 YLLs [1470·9–1663·4] per 
100 000 people; figure 4A), while the YLD rate accounted 
for a minority share of 641·6 YLDs (541·1–727·9) per 
100 000 people (figure 4B). In the high-income super-
region, by contrast, the composition of DALYs was 
comparatively more balanced, with 688·8 YLLs and 
702·0 YLDs per 100 000 people (figure 4). When 
considering specific diseases, similar findings were 
observed with respect to morbidity: COPD accounted for 
the majority of chronic respiratory disease-associated 
DALYs, while asthma was the second leading cause of 
morbidity (figure 4). Similar to prevalence and mortality, 
age-standardised DALY rates for chronic respiratory 
diseases decreased by 38·2% between 1990 (2304·36 
DALYs [2138·52–2422·37] per 100 000 people) and 2017 
(1422·89 DALYs [1326·65–1517·23] per 100 000 people). 
Smoking was the most prevalent risk factor for 
chronic respiratory diseases worldwide, responsible for 
396·4 DALYs (355·1–435·5) per 100 000 people 
(27·0% [24·5–29·6] of chronic respiratory disease-
attributable DALYs; figure 5). Smoking accounted for the 
largest fraction of all chronic respiratory disease 
morbidity in all super-regions except sub-Saharan Africa 
(80·5 [67·4–94·2] DALYs per 100 000 people; 10·2% 
[8·5–11·9]), where household air pollution (105·5 DALYs 
[77·0–132·7] per 100 000 people) and occupational risks 
(89·9 DALYs [79·6–100·7] per 100 000 people) were more 
prominent factors. These findings were not consistent 
across sexes, however, as exposure to household air 
pollution from solid fuels was the leading risk factor 
among women globally, and in south Asia and 
sub-Saharan Africa. In addition, among women, 
household air pollution from solid fuels represented the 
leading risk factor in the south Asia and the southeast 
Asia, east Asia, and Oceania super-regions. In these two 
super-regions smoking accounted for the lowest fraction 
for women but the greatest fraction for men. Smoking-
attributable DALYs were the lowest in the north Africa 
and Middle East and the sub-Saharan Africa super-
regions (figure 5; appendix 3).
Discussion
This study shows that chronic respiratory diseases 
remain a leading cause of disability and death worldwide, 
with the highest prevalence (10–11% of the population or 
higher) observed in high-income regions, a finding 
unchanged since first estimated in 1990. In south Asia, 
although crude prevalence is lower than that in most 
other super-regions, morbidity and mortality attributable 
to chronic respiratory diseases are the highest in the 
world. Much of this burden is the result of premature 
mortality. In general, progress has been modest in 
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alleviating chronic respiratory disease burden over the 
past 30 years, with the largest reductions observed in 
Latin America. COPD remains the most prevalent of 
chronic respiratory diseases globally among men and 
women, with crude prevalence rising globally in absolute 
terms. This change is probably due to population ageing 
and longer life expectancies, particularly in high-income 
areas, although improved diagnosis cannot be ruled out. 
However, from 1990 to 2017, the prevalence, mortality, 
and DALY rates per 100 000 people dropped by 14·3%, 
42·6%, and 38·2%, respectively, if we adjust for 
population growth and ageing. These sharp declines 
might be the result of a long list of factors, including 
global or regional success in tobacco control measures, 
paired with reductions in environmental pollution in 
cities, more electric cars, cleaner working environments, 
better information and prevention with regard to 
allergens, better treatment of respiratory and non-
respiratory comorbidities, and reductions of universally 
high rates of underdiagnosis of chronic respiratory 
diseases. Although smoking is the leading risk factor for 
DALYs related to chronic respiratory diseases across all 
regions for men, other risk factors such as household 
and ambient air pollution have substantial effects on 
women across Asia and Africa.
Interpretation of counts and absolute rates is 
straightforward. We also present the results as age-
standardised rates in appendix 1 (pp 62–66). Crude 
estimates provide the real situation in each country, 
which is useful for policy makers and practising 
physicians, whereas age-standardised estimates allow 
comparisons over time and between countries after 
adjusting for the differences in the age structure and 
population growth of the population for a specific year. 
For grasping the current burden of all chronic respiratory 
diseases in the short period from 1990 to 2017, 
representing only one generation, we suggest the overall 
picture of counts and crude rates to be simpler and more 
useful. However, for longer periods, the use of age-
standardised rates is much more appropriate, and even 
necessary. Predicted values for all-age standardised 
mortality for COPD by GBD super-region in 2040 are 
already available through GBD Foresight.26 In addition, 
all estimates for each of the 195 individual countries or 
territories are available in appendix 2.
Given the high mortality rates due to chronic 
respiratory diseases in south Asia, increased attention 
and resources should be allocated to this category of 
diseases, which are often given less focus than chronic 
cardiovascular ailments, diabetes, or cancer.27 Multiple 
potential policy solutions exist that could help to make 
progress in the regions where high YLL rates account for 
the majority of chronic respiratory disease-related DALYs. 
First, as respiratory diseases are often difficult to 
diagnose28 in resource-constrained settings because of 
the widespread lack of important diagnostic equipment 
(eg, spirometry and radiography equipment), ensuring 
that such capabilities are part of any primary health-care 
Figure 3: All-age mortality rates of chronic respiratory diseases by disease category across super-regions in 2017
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strategy is crucial for improving time to diagnosis and 
early intervention.4
Second, most risk factors for chronic respiratory 
diseases are preventable. As we report, in south Asia and 
in southeast Asia, east Asia, and Oceania, ambient indoor 
and outdoor air pollution cause a far greater share of 
chronic respiratory disease-attributable disability than 
they do in the high-income super-region and the central 
Europe, eastern European, and central Asia super-region, 
where greater affluence correlates with higher smoking-
attributable disease. Different strategies to minimise 
exposure to these well known risk factors have been 
previously described and remain underutilised globally. 
For example, for tobacco, WHO advocates measures 
such as banning advertising, creating tobacco-free 
spaces, inserting health warnings on the packaging of 
tobacco products, and increased cigarette taxation.29 New 
assessments on the effects of exposure to second-hand 
smoke,30 and of new forms of smoking, such as electronic 
cigarettes,31 on health, particularly among children and 
adolescents, deserve heightened public awareness.
The general limitations of GBD studies have been 
reported elsewhere and additionally apply to estimates of 
chronic respiratory diseases,10,25 although there are some 
limitations specific to chronic respiratory diseases. Notably, 
distinguishing between the different chronic respiratory 
disease diagnoses requires clear case definitions, which 
are often not standardised across countries because of the 
intrinsic difficulty and resource-intensive nature of 
accurately diagnosing a chronic respiratory disease. 
Figure 4: Chronic respiratory disease-attributable YLL rates (A) and YLD rates (B) across super-regions in 2017
YLL=years of life lost. YLD=years lived with disability.
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However, initiatives to better define asthma, COPD, and 
their disease mimics are currently in progress.32 For 
diagnoses such as interstitial lung disease, pulmonary 
sarcoidosis, and pneumoconiosis, in particular, almost all 
of our input data for prevalence are derived from hospital 
inpatient records and insurance claims—a major 
limitation because claims data can be unreliable and 
highly dependent on the methods for denominator 
estimation and bias correction. Moreover, for conditions 
such as pneumoconiosis, prevalence studies have typically 
been done in small, non-representative groups (eg, 
employees in a particular occupation), which are not 
included in GBD. Taken together, these limitations 
highlight the need for enhanced data collection efforts 
through the use of more precise and standardised case 
definitions to help improve cross-country comparisons.
In addition, with regard to COPD, defining the cutoff 
value for spirometry with the lower limit of normal as the 
fifth percentile in a healthy reference population makes 
the uneasy assumption that COPD prevalence cannot be 
lower than 5%. Recent evidence has identified near-perfect 
pattern recognition and diagnosis through spirometric 
manoeuvres by machine learning algorithms,33 which are 
likely to overcome the poor repeatability of human-based 
interpretation of spirometry. All included COPD surveys 
were spirometry-based, and we chose the Global Initiative 
for Chronic Obstructive Lung Disease post-bronchodilator 
fixed ratio lower than 0·7 as a reference value; different 
spirometry-based case definitions showed a strong age 
pattern, which we tried to capture with regression 
methods. These adjustments add un certainty, which 
would be avoided if estimates were all reported in a 
standard manner.10
Asthma diagnosis relies on self-report of wheeze in the 
past 12 months and self-report of a physician diagnosis, 
because no physiological measurement is considered a 
gold standard. Thus, measurement of asthma prevalence 
is subject to the limitations of recall bias, access to health 
services, and the different interpretations of survey 
questions inherent in self-reported health measurements.
Therefore, in all chronic respiratory diseases, and in 
particular interstitial lung disease and pulmonary 
sarcoidosis, definition is highly dependent on medical 
expertise and equipment, and it is likely that a significant 
source of geographical variation is the lack of adequate 
diagnosis in less-developed areas.27,34
For many countries without functional vital registration 
systems, we had to rely on death estimates of all chronic 
respiratory diseases collectively from verbal autopsy 
studies, as these studies cannot distinguish between 
asthma, COPD, or other chronic respiratory diseases. 
Initiatives to strengthen vital registration systems are key 
to improving population health measurement. Of note, 
the residual group of other chronic respiratory diseases 
includes many heterogeneous conditions, some very 
prevalent, including rhinitis3,35 and sleep apnoea.36 These 
conditions merit greater attention in future GBD cycles. 
The estimation of any specific chronic respiratory disease 
would benefit from greater precision, both in the primary 
data and in the analytical methods, in distinguishing 
between and within chronic respiratory disease categories 
that often have many overlapping diagnostic criteria.37
Figure 5: Chronic respiratory disease-attributable DALY rates by risk factor across super-regions in 2017
DALY=disability-adjusted life-year.
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Finally, incorporating new evidence and analytical 
strategies for risk factors associated with chronic 
respiratory diseases, particularly on all types of 
smoking—from cigarettes38 to new forms of heat-not-
burn technologies such as vaping—is needed to 
accurately capture the changing landscape of risk factors 
for chronic respiratory ailments.30,39 Additionally, the 
issue of confounding between air pollution and smoking 
has not been addressed.40 Analyses that take these 
confounders into account would be a future aim of the 
project. For instance, no attributable risk factor analyses 
could be done for interstitial lung disease and pulmonary 
sarcoidosis with the currently available evidence.
Chronic respiratory diseases are important contributors 
to the burden of NCDs. Although much of the burden 
is either preventable or treatable with affordable 
interventions, these diseases have received less attention 
than other prominent NCDs such as cardiovascular 
disease, diabetes, and cancer.41 Although global age-
standardised morbidity and mortality rates for chronic 
respiratory diseases dropped substantially between 1990 
and 2017, the fact that chronic respiratory disease 
prevalence is increasing in absolute terms in high-
income nations despite the availability of robust health-
care services suggests that either some risk factors have 
not been sufficiently addressed or provisioning of 
resources to address this persistent burden remains 
inadequate.
Up-to-date population-level estimates on these common 
respiratory conditions is key to effective policy making with 
the aim of improving access to care and scaling of robust 
prevention strategies. We call for greater stan dardisation in 
data collection with regard to case definitions and severity 
distributions of all NCDs in general, and chronic respiratory 
diseases in particular. More and updated population 
measurements of chronic respiratory diseases are needed 
to better quantify the size of the problem and to better 
monitor progress towards achievement of the 2030 health-
related Sustainable Development Goals.42
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